A CANCER drug that was trialled at Queen Alexandra Hospital could be cut from the NHS after being deemed too expensive. NHS watchdog the National Institute for Health and Care Excellence announced Kadcyla, also called trastuzumab emtansine, cost too much to be covered by funding.